Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $3,157,086.47 in Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Ryan Savitz sold 31,249 shares of Dianthus Therapeutics stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $101.03, for a total value of $3,157,086.47. Following the completion of the sale, the executive vice president owned 31,249 shares in the company, valued at $3,157,086.47. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Dianthus Therapeutics Stock Down 1.4%

Shares of Dianthus Therapeutics stock opened at $99.91 on Thursday. The business’s fifty day simple moving average is $88.39 and its 200-day simple moving average is $73.15. Dianthus Therapeutics, Inc. has a 52 week low of $18.08 and a 52 week high of $102.37. The firm has a market cap of $5.46 billion, a PE ratio of -24.19 and a beta of 1.20.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. The firm had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. As a group, equities analysts expect that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Handelsbanken Fonder AB acquired a new position in Dianthus Therapeutics in the second quarter valued at $1,491,000. Assenagon Asset Management S.A. acquired a new stake in Dianthus Therapeutics in the 2nd quarter worth about $27,358,000. Seven Fleet Capital Management LP boosted its stake in Dianthus Therapeutics by 451.6% in the 1st quarter. Seven Fleet Capital Management LP now owns 80,809 shares of the company’s stock worth $6,781,000 after buying an additional 66,158 shares during the last quarter. DV Trading LLC purchased a new stake in Dianthus Therapeutics in the 1st quarter valued at about $2,228,000. Finally, Glenmede Trust Co. NA grew its holdings in Dianthus Therapeutics by 96.5% in the 1st quarter. Glenmede Trust Co. NA now owns 12,470 shares of the company’s stock valued at $1,046,000 after buying an additional 6,125 shares during the period. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Analysts Set New Price Targets

DNTH has been the topic of several recent research reports. TD Cowen reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wedbush upped their target price on Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. Wolfe Research reiterated an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Raymond James Financial reissued a “strong-buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Dianthus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $117.82.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.